CRANBURY, N.J., May 8, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2013. The conference call will include an update on development of bremelanotide for female sexual dysfunction, including plans for Phase 3 clinical trials and results of the end-of-Phase 2 meeting with the U.S. Food and Drug Administration.
|
Schedule for the Financial Results Press Release, Conference Call / Webcast |
|
|
5/14/2013 at 7:30 a.m. ET
|
|
5/14/2013 at 11:00 a.m. ET 1-888-427-9419 1-719-457-2648 8591699 |
|
5/14/2013-5/21/2013 1-888-203-1112 1-719-457-0820 8591699 |
|
http://www.palatin.com |
|
The webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts” section of Palatin’s website at http://www.palatin.com |
|
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com or follow us on Twitter at http://twitter.com/PalatinTech.
SOURCE Palatin Technologies, Inc.